Bernat Olle, Vedanta Biosciences CEO

Vedan­ta brings home a win for lead mi­cro­bio­me pro­gram, pass­ing a PhII test and clinch­ing BAR­DA in­vest­ment

Vedan­ta Bio­sciences wrapped up a Se­ries D about two months ago to ad­vance its mi­cro­bio­me re­search, but it’s not con­tent to rest on its lau­rels.

The Cam­bridge, MA-based biotech claimed a win in a Phase II study treat­ing Clostrid­ioides dif­fi­cile in­fec­tion, say­ing its lead pro­gram achieved a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in re­cur­rences af­ter eight weeks com­pared with place­bo. It’s a re­sult that os­ten­si­bly im­pressed the US gov­ern­ment as the study re­sults trig­gered a $23.8 mil­lion op­tion from BAR­DA.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters